{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:23:12Z","timestamp":1774866192187,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10549-024-07466-9","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T15:02:05Z","timestamp":1724511725000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast"],"prefix":"10.1007","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-3697","authenticated-orcid":false,"given":"Camila Vitola","family":"Pasetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-9019","authenticated-orcid":false,"given":"Fernando Nalesso","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8837-0017","authenticated-orcid":false,"given":"Marcella Bassan","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-2863","authenticated-orcid":false,"given":"Ma\u00edra Teixeira","family":"D\u00f3ria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-1066","authenticated-orcid":false,"given":"Bruna Salani","family":"Mota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1725-8732","authenticated-orcid":false,"given":"Jonathan Yugo","family":"Maesaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1192-4220","authenticated-orcid":false,"given":"Jos\u00e9 Roberto","family":"Filassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-9030","authenticated-orcid":false,"given":"Edmund Chada","family":"Baracat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-0214","authenticated-orcid":false,"given":"Rodrigo","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"issue":"3","key":"7466_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"7466_CR2","unstructured":"INCA (2022) ESTIMATIVA 2023 Incid\u00eancia de C\u00e2ncer no Brasil. Rio de Janeiro: https:\/\/www.inca.gov.br\/publicacoes\/livros\/estimativa-2023-incidencia-de-cancer-no-brasil"},{"issue":"6","key":"7466_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67(6):439\u2013448","journal-title":"CA Cancer J Clin"},{"key":"7466_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135\u2013144","journal-title":"Breast Cancer Res Treat"},{"key":"7466_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41379-020-00665-x","volume":"34","author":"SJ Schnitt","year":"2021","unstructured":"Schnitt SJ (2021) Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy. Mod Pathol 34:1\u20137","journal-title":"Mod Pathol"},{"key":"7466_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/cncr.20979","volume":"103","author":"LC Collins","year":"2005","unstructured":"Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ (2005) Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the nurses\u2019 health study. Cancer 103:1778\u20131784","journal-title":"Cancer"},{"key":"7466_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) \u2013 Breast Cancer version 4\u20132022. NCCN (2022)"},{"key":"7466_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-011-1387-4","volume":"127","author":"SY Wang","year":"2011","unstructured":"Wang SY, Shamliyan T, Virnig BA, Kane R (2011) Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 127:1\u201314","journal-title":"Breast Cancer Res Treat"},{"key":"7466_CR9","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, Ryser MD, Partridge AH et al (2017) Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol 24:3534\u20133540","journal-title":"Ann Surg Oncol"},{"key":"7466_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L et al (2015) Feasibility of a prospective, randomized, open-label, international multicenter, phase III, non-inferiority trial to assess the safety of active surveillance for low-risk ductal carcinoma in situ\u2014the LORD study. Eur J Cancer 51:1497\u20131510","journal-title":"Eur J Cancer"},{"key":"7466_CR11","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Stempel M, Rosenfeld H, Eaton A, Van Zee KJ, Morrow M (2016) Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma? Ann Surg Oncol 23:3487\u20133493","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"7466_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","volume":"105","author":"LJ Solin","year":"2013","unstructured":"Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701\u2013710","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7466_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2022.06.072","volume":"115","author":"FA Vicini","year":"2023","unstructured":"Vicini FA, Mann GB, Shah C, Weinmann S, Leo MC, Whitworth P et al (2023) A novel biosignature identifies patients with DCIS with high risk of local recurrence after breast conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 115(1):93\u2013102","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7466_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.pathol.2019.07.005","volume":"51","author":"SS Badve","year":"2019","unstructured":"Badve SS, G\u00f6kmen-Polar Y (2019) Ductal carcinoma in situ of breast: update 2019. Pathology 51:563\u2013569","journal-title":"Pathology"},{"issue":"1","key":"7466_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE et al (2018) Tumour- infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40\u201350","journal-title":"Lancet Oncol"},{"key":"7466_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.breast.2021.07.007","volume":"59","author":"R Caparica","year":"2021","unstructured":"Caparica R, Bruzzone M, Agostinetto E, Franzoi MA, Ceppi M, Radosevic-Robin N et al (2021) Tumour-infiltrating lymphocytes in non-invasive breast cancer: a systematic review and meta-analysis. Breast 59:183\u2013192","journal-title":"Breast"},{"issue":"10","key":"7466_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F et al (2017) Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov 7(10):1098\u20131115","journal-title":"Cancer Discov"},{"key":"7466_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.18.02157","volume":"37","author":"A Kov\u00e1cs","year":"2019","unstructured":"Kov\u00e1cs A, Tullberg AS, R\u00f6nnerman EW, Holmberg E, Hartman L, Sj\u00f6str\u00f6m M et al (2019) Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial. J Clin Oncol 37:1179\u20131187","journal-title":"J Clin Oncol"},{"key":"7466_CR19","doi-asserted-by":"crossref","unstructured":"Wu SL, Yu X, Mao X, Jin F (2022) Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis. BMC Cancer 22(1)","DOI":"10.1186\/s12885-022-09883-9"},{"issue":"3","key":"7466_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN et al (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249\u2013258","journal-title":"Mod Pathol"},{"key":"7466_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS Working Group 2014. Ann Oncol 26:259\u2013271","journal-title":"Ann Oncol"},{"key":"7466_CR22","doi-asserted-by":"crossref","unstructured":"Farolfi A, Petracci E, Serra L, Ravaioli A, Bravaccini S, Ravaioli S et al (2020) Tumor-infiltrating lymphocytes (TILs) and risk of a second breast event after a ductal carcinoma in situ. Front Oncol 10","DOI":"10.3389\/fonc.2020.01486"},{"issue":"2","key":"7466_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A et al (2017) The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol 28(2):321\u2013328","journal-title":"Ann Oncol"},{"key":"7466_CR24","doi-asserted-by":"crossref","unstructured":"Beguinot M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C et al (2018) Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer 18(1)","DOI":"10.1186\/s12885-018-4013-6"},{"issue":"10","key":"7466_CR25","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1245\/s10434-019-07562-x","volume":"26","author":"F Darvishian","year":"2019","unstructured":"Darvishian F, Ozerdem U, Adams S, Chun J, Pirraglia E, Kaplowitz E et al (2019) Tumor-infiltrating lymphocytes in a contemporary cohort of women with ductal carcinoma in situ (DCIS). Ann Surg Oncol 26(10):3337\u20133343","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"7466_CR26","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","volume":"23","author":"S Hendry","year":"2017","unstructured":"Hendry S, Pang JMB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG et al (2017) Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res 23(17):5210\u20135217","journal-title":"Clin Cancer Res"},{"key":"7466_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","volume":"177","author":"X-Y Chen","year":"2019","unstructured":"Chen X-Y, Yeong J, Thike AA, Bay BH, Tan PH (2019) Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat 177:17\u201327. https:\/\/doi.org\/10.1007\/s10549-019-05272-2","journal-title":"Breast Cancer Res Treat"},{"key":"7466_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.breast.2008.06.001","volume":"17","author":"B-C Sheu","year":"2008","unstructured":"Sheu B-C, Kuo W-H, Chen R-J, Huang S-C, Chang K-J, Chow S-N (2008) Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 17:604\u2013610. https:\/\/doi.org\/10.1016\/j.breast.2008.06.001","journal-title":"Breast"},{"issue":"3","key":"7466_CR29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-20-3299","volume":"27","author":"AS Tullberg","year":"2021","unstructured":"Tullberg AS, Puttonen HAJ, Sj\u00f6str\u00f6m M, Holmberg E, Laura Chang S, Feng FY et al (2021) Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer: results from the randomized SweBCG91RT trial. Clin Cancer Res 27(3):749\u2013758","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07466-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T11:18:24Z","timestamp":1728040704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07466-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7466"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07466-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"15 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}